A Phase 4 interventional study of Genotyping guided therapy for anti-platelet management in High Risk Bleeding, sponsored by Ottawa Heart Institute Research Corporation. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Ottawa Heart Institute Research Corporation · Phase 4, Interventional, and Prevention
RAPID PREVENT aims to identify if a personalized (targeted) anti-platelet strategy will reduce bleeding events when compared to the current standard anti-platelet therapy.
RAPID PREVENT is a Phase IV, single centre, physician initiated, cluster randomized pilot trial evaluating a personalized antiplatelet strategy for patients with acute coronary syndrome (ACS) with High Bleeding Risk (HBR) undergoing percutaneous coronary intervention (PCI). Monthly clusters are randomized 1:1 to either standard of care or personalized therapy guided by HBR algorithm and point of care CYP2C19 genotyping.
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
This study's planned enrollment of 1,760 is above the median of 83 across 530 interventional studies indexed under Thrombosis.
Browse Thrombosis studies →Ottawa Heart Institute Research Corporation is the lead sponsor of 182 studies on the registry; 42 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants randomized to standard of care will receive the standard treatment for this condition.
Participants randomized to this arm will completed a point of care genotyping test to determine the presence or absence of the CYP2C19 gene, and the anti-platelet therapy will be determined by if the gene is present or not.
Drug: Genotyping guided therapy for anti-platelet management
Participants that are carriers of the CYP2C19 gene will receive either Ticagrelor monotherapy, or dual therapy with Ticagrelor and Aspirin. Participants that are not carriers of the CYP2C19 gene will receive either Plavix monotherapy or dual therapy with Plavix and Aspirin.
Bleeding Events
Events that meet the BARC Type 2, 3, or 5 definitions.
Time frame: Randomization to 12months
MACCE Events
Composite of events of cardiovascular death, non-fatal myocardial infarction, stroke, and repeat revascularization.
Time frame: Randomization to 12months
CV mortality
Incidences of mortality associated with cardiovascular disease
Time frame: randomization to 12months
Non-Fatal MI
Number of incidences of non-fatal myocardial infarctions
Time frame: Randomization to 12months.
Stroke
Number of stroke events that occur
Time frame: randomization to 12months
Repeat revascularization
Incidences of events requiring additional unplanned revascularization procedures post randomization.
Time frame: Randomization to 12months
Stent Thrombosis
Incidences of identified thrombosis of previous stents.
Time frame: Randomization to 12months.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ottawa Heart Institute Research Corporation →